Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma.

ABSTRACT:

Background/aims

Chronic hepatitis B (CHB) is a risk factor for non-Hodgkin lymphoma (NHL). Our recent study suggested that antiviral treatment may reduce the incidence of NHL in CHB patients. This study compared the prognoses of hepatitis B virus (HBV)-associated diffuse large B-cell lymphoma (DLBCL) patients receiving antiviral treatment and HBV-unassociated DLBCL patients.

Methods

This study comprised 928 DLBCL patients who were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) at two referral centers in Korea. All patients with CHB received antiviral treatment. Time-to-progression (TTP) and overall survival (OS) were the primary and secondary endpoints, respectively.

Results

Among the 928 patients in this study, 82 were hep

SUBMITTER: Park J 

PROVIDER: S-EPMC10366791 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature